Neuronal autoantibodies associated with cognitive impairment in melanoma patients. (6th March 2019)

• Record Type: Journal Article
• Authors: Bartels, F; Strönisch, T; Farmer, K; Rentzsch, K; Kiecker, F; Finke, C
• Is Part Of: Annals of oncology. Volume 30:Number 5(2019)
• Page Start: 823
• Page End: 829
• Publication Date: 2019-03-06
• Subjects: melanoma -- cancer-related cognitive impairment -- neuronal autoantibodies -- paraneoplastic neurological syndromes -- immune checkpoint inhibitor; Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdz083
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: Cancer-related cognitive impairment is an important complication in cancer patients, yet the underlying mechanisms remain unknown. Over the last decade, the field of paraneoplastic neurological syndromes has been dramatically changed by the discovery of new neuronal autoantibodies, some of them associated with cognitive impairment. We aimed to assess the prevalence of neuronal autoantibodies in melanoma patients and their association with neurological and cognitive dysfunction. Patients and methods: A total of 157 consecutive melanoma patients with a median age of 63 years were recruited at the Department of Dermatology, Charité—Universitätsmedizin Berlin and tested for neuronal autoantibodies. A comprehensive neuropsychological assessment was carried out in a selected subgroup of 84 patients after exclusion of patients with confounding factors for a cognitive dysfunction, including brain metastases, relevant medication, and neurological disorders. Results: Neuronal autoantibodies were found in 22.3% of melanoma patients. The most frequent antibodies were IgA/IgM anti-NMDAR antibodies. Applying the International Cognition and Cancer Task Force criteria, 36.9% had cognitive impairment, however, with a threefold higher odds in antibody-positive compared with antibody-negative patients (57.1% versus 30.2%, OR = 3.1, 95% CI: 1.1 to 8.6; P = 0.037). In patients with anti-NMDAR antibodies, this impairment increased with higher antibody titers ( P = 0.007). Antibody-positive patients had a significantly impaired overall cognitive performance ( z -value: −0.38 ± 0.69 versus 0.00 ± 0.56; P = 0.014) as well as significant impairments in tests of memory, attention, and executive function. In a multiple linear regression analysis, autoantibodies were an independent risk factor for cognitive impairment (B = −0.282; 95% CI: −0.492 to −0.071; P = 0.009). Autoantibody seropositivity was associated with immune checkpoint inhibitor treatment and a history of autoimmune diseases. Conclusions: A large number of melanoma patients harbor neuronal autoantibodies that are associated with significant cognitive impairment affecting memory, attention, and executive function. Neuronal autoantibodies might represent a pathophysiological factor and possible biomarker in the development of cancer-related cognitive impairment.